| AGREEMENT |
Bristol-Myers, Iconix in pact Iconix Pharmaceuticals has entered a research and license agreement with Bristol-Myers Squibb, allowing BMS access to Iconix' DrugMatrix chemogenomics system and its library of Drug Signatures. DrugMatrix is a reference source of information on the genomic effects of drug and chemical treatments. The agreement calls for Iconix to work on several projects each year involving proprietary BMS compounds. If the agreement runs its full term, the total value to Iconix--excluding commercialization fees and royalties--would be $24 million |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |